Menu
Search
|

Menu

Close
X

Apellis Pharmaceuticals Inc APLS.OQ (NASDAQ Stock Exchange Global Select Market)

14.95 USD
-0.99 (-6.21%)
As of Feb 17
chart
Previous Close 15.94
Open 15.97
Volume 37,883
3m Avg Volume --
Today’s High 16.00
Today’s Low 14.27
52 Week High 25.33
52 Week Low 12.51
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-0.235
FY16
-0.281
FY15
-0.800
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
--
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Gerald Chan
Chairman of the Board, Since 2016
Salary: --
Bonus: --
Cedric Francois
President, Chief Executive Officer, Co-Founder, Director, Since 2016
Salary: $275,000.00
Bonus: $137,000.00
Pascal Deschatelets
Co-Founder, Chief Operating Officer, Since 2016
Salary: --
Bonus: --
Alec Machiels
Co-Founder, Director, Since 2016
Salary: --
Bonus: --
Daniel Geffken
Interim Chief Financial Officer, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

6400 Westwind Way Ste a
CRESTWOOD   KY   40014-6773

Phone: +1502.2414114
Site: apellis.com/

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.

SPONSORED STORIES